{"product_id":"active-surveillance-for-micropapillary-thyroid-carcinoma-a-patients-guide-to-understanding-your-options","title":"Active Surveillance for Micropapillary Thyroid Carcinoma: A Patient's Guide to Understanding Your Options","description":"\u003cp\u003eActive surveillance—careful monitoring instead of immediate surgery—is a safe and effective strategy for managing micropapillary thyroid carcinoma (a small thyroid cancer measuring less than 1 centimeter), according to this comprehensive clinical review by experts from Memorial Sloan Kettering Cancer Center. The review examines data from major international studies involving thousands of patients, showing that fewer than 10% of tumors grow during observation, only 2–3% develop lymph node metastasis, and no patients under active surveillance have died from thyroid cancer. The authors provide detailed guidance on identifying ideal candidates for this approach, monitoring strategies, and when surgery becomes necessary.\u003c\/p\u003e\n\n\u003ch1\u003eActive Surveillance for Micropapillary Thyroid Carcinoma: A Patient's Guide to Understanding Your Options\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: The Rising Diagnosis of Tiny Thyroid Cancers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#concepts\"\u003eThe Concepts Behind Active Surveillance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#philosophy\"\u003eThe Philosophy of Management: Why Observation Makes Sense\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-scenario\"\u003eReal Clinical Scenarios: How This Plays Out in Practice\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ideal-candidates\"\u003eWho Should Be Referred for Active Surveillance?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#strategy\"\u003eThe Observational Approach: What Monitoring Looks Like\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgical-indications\"\u003eWhen Surgery Becomes Necessary\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#decision-making\"\u003eMedical Decision Making: Maximalist vs. Minimalist Approaches\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#adverse-features\"\u003eAdverse Features of Papillary Microcarcinoma\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations and Uncertainties\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eActive surveillance is safe for micropapillary thyroid carcinoma; fewer than 10% of tumors grow and only 2-3% develop lymph node metastasis.\u003c\/li\u003e\n\u003cli\u003eNo patients under active surveillance have died from thyroid cancer in published studies.\u003c\/li\u003e\n\u003cli\u003eIdeal candidates are over 60, have a single well-defined nodule, no lymph node metastasis, and can comply with follow-up.\u003c\/li\u003e\n\u003cli\u003eMonitoring involves ultrasound every 6 months initially, then annually; surgery is considered if tumor grows \u0026gt;3 mm or new nodes appear.\u003c\/li\u003e\n\u003cli\u003eAbout 10% of patients switch to surgery, often due to anxiety rather than tumor progression.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: The Rising Diagnosis of Tiny Thyroid Cancers\u003c\/h2\u003e\n\n\u003cp\u003eThe rapid rise in thyroid cancer incidence is well documented worldwide. In the United States, the incidence of thyroid cancer has risen almost \u003cstrong\u003efour times\u003c\/strong\u003e over the last quarter century, while in South Korea it has risen approximately \u003cstrong\u003e15 times\u003c\/strong\u003e. This dramatic increase is primarily related to incidentally detected micropapillary carcinomas—tiny thyroid cancers found during routine ultrasound evaluations of the thyroid, often for unrelated reasons.\u003c\/p\u003e\n\n\u003cp\u003eThis surge has resulted in what experts call overdiagnosis and overtreatment. Interestingly, likely due to growing appreciation of this problem, thyroid cancer rates have actually \u003cstrong\u003efallen in Korea and stabilized in the United States\u003c\/strong\u003e in recent years. The medical community has generated considerable debate about the impact of diagnosing and treating these tiny cancers on patient outcomes and healthcare costs.\u003c\/p\u003e\n\n\u003cp\u003eHistorically, the standard of care for any thyroid cancer diagnosis was an appropriate thyroidectomy (surgical removal of the thyroid gland). However, the old dictum of routinely using radioactive iodine has been essentially abandoned in patients with micropapillary carcinoma. Today, treatment choices include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eLobectomy (removal of one lobe of the thyroid)\u003c\/li\u003e\n  \u003cli\u003eTotal thyroidectomy (removal of the entire thyroid)\u003c\/li\u003e\n  \u003cli\u003eTotal thyroidectomy with central compartment dissection (removal of lymph nodes in the central neck)\u003c\/li\u003e\n  \u003cli\u003eTotal thyroidectomy with radioactive iodine treatment\u003c\/li\u003e\n  \u003cli\u003eNewer ablative techniques such as radiofrequency ablation or laser\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActive surveillance\u003c\/strong\u003e (careful monitoring without immediate surgery)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eClearly, it would be almost impossible to operate on every micropapillary carcinoma diagnosed as an incidental finding. Autopsy studies frequently identify incidental, asymptomatic micropapillary carcinoma—meaning many people live with these tiny cancers without ever knowing. As the authors put it: \"People live with it, they grow with it, and most of them will die with it and not of it.\"\u003c\/p\u003e\n\n\u003cp\u003eThere are, of course, legitimate concerns about thyroid surgery, including neck scarring, complications and side effects of surgery, the need for lifetime thyroid medication, and lifelong follow-up. Even though most patients do well with thyroid replacement therapy, there are quality-of-life concerns after thyroidectomy that deserve careful consideration.\u003c\/p\u003e\n\n\u003ch2 id=\"concepts\"\u003eThe Concepts Behind Active Surveillance\u003c\/h2\u003e\n\n\u003cp\u003eThe concept of active surveillance for micropapillary thyroid carcinoma was first proposed in \u003cstrong\u003e1993\u003c\/strong\u003e by Dr. Miyauchi from Kobe, Japan, after careful consideration of the natural history of these tumors. He and his team conducted a landmark study involving approximately \u003cstrong\u003e2,153 patients\u003c\/strong\u003e with microcarcinoma—55% of whom were on active surveillance while 45% underwent immediate surgery. This number continues to grow as more patients agree to active surveillance.\u003c\/p\u003e\n\n\u003cp\u003eThe results were striking. The disease remained stable in more than \u003cstrong\u003e92% of patients\u003c\/strong\u003e. Approximately \u003cstrong\u003e5% of patients\u003c\/strong\u003e eventually went to surgery, either because of an increase in tumor size or the patient's unwillingness to continue monitoring. New appearance of lymph node metastasis was noted in less than \u003cstrong\u003e1%\u003c\/strong\u003e, and an increase in the size of the primary tumor occurred in only \u003cstrong\u003e3%\u003c\/strong\u003e of patients.\u003c\/p\u003e\n\n\u003cp\u003eFrom all active surveillance studies combined, the data consistently show that \u003cstrong\u003eless than 10% of tumors will grow\u003c\/strong\u003e and approximately \u003cstrong\u003e2–3% will develop nodal metastasis\u003c\/strong\u003e over 5–10 years of observation—none of which has a major impact on long-term outcomes. Critically, \u003cstrong\u003eno patients under active surveillance have died of thyroid cancer\u003c\/strong\u003e or developed major cancer-related problems in any of the published studies.\u003c\/p\u003e\n\n\u003cp\u003eIn 2017, Tuttle and colleagues from Memorial Sloan Kettering Cancer Center (MSK) published their large series of approximately \u003cstrong\u003e291 patients\u003c\/strong\u003e—the first study of its kind in the United States. Continued surveillance was maintained in \u003cstrong\u003e96% of patients\u003c\/strong\u003e. Approximately 4% underwent surgery due to an increase in tumor size or concerns of the patient and family. None of the patients died of thyroid cancer.\u003c\/p\u003e\n\n\u003ch2 id=\"philosophy\"\u003eThe Philosophy of Management: Why Observation Makes Sense\u003c\/h2\u003e\n\n\u003cp\u003eWith active surveillance, immediate surgery is avoided in favor of continuous monitoring. This approach is known by several names: active monitoring, expectant management, vigilant observation, watchful masterly inactivity, or deferred intervention. The key principle is that this is not inferior treatment—it is a deliberate, evidence-based choice for appropriately selected patients.\u003c\/p\u003e\n\n\u003cp\u003eOne of the challenges revolves around the nomenclature used by pathologists—the word \"cancer.\" As the \"C\" word is unsettling for most patients, who understandably worry about tumor growth, family responsibilities, or even death, some practitioners have proposed changing the name to \u003cstrong\u003epapillary microtumor\u003c\/strong\u003e or \u003cstrong\u003eIDLE (Indolent Lesion of Epithelial Origin)\u003c\/strong\u003e. The authors believe most patients will understand the philosophy of observation if we use the analogy of prostate cancer and continuous monitoring, which has become widely accepted in urology.\u003c\/p\u003e\n\n\u003cp\u003eIt is important to train primary care physicians, who are often the first to meet with patients, about the benefits of active surveillance. There should also be more publicly available information and education about this approach. Active surveillance is not inappropriate management—it may be considered as \u003cstrong\u003edeferred intervention\u003c\/strong\u003e in properly selected patients.\u003c\/p\u003e\n\n\u003cp\u003ePhysicians sometimes worry about medicolegal issues, but expansion of public knowledge will help address these concerns. It is crucial to develop well-defined selection criteria and standardized follow-up protocols to offer patients. Patients can change their mind at any time and opt for surgery. The success of an active surveillance program requires multidisciplinary involvement with surgeons, endocrinologists, radiologists, and other physicians working together as a disease management team.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-scenario\"\u003eReal Clinical Scenarios: How This Plays Out in Practice\u003c\/h2\u003e\n\n\u003cp\u003eThe principles behind active surveillance become clearer when considering real patient scenarios. The authors present two contrasting cases:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCase 1:\u003c\/strong\u003e An \u003cstrong\u003e85-year-old man\u003c\/strong\u003e undergoes a routine carotid ultrasound and the sonographer finds a \u003cstrong\u003e5-mm nodule\u003c\/strong\u003e in the right lobe of the thyroid. The family insists he undergo a fine-needle aspiration biopsy of this tiny nodule, which is reported to be papillary carcinoma. What now? The authors note that very few surgeons or endocrinologists would mandate immediate surgical intervention in this scenario. It is quite likely this nodule has been there for a while and can be easily monitored.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCase 2:\u003c\/strong\u003e A \u003cstrong\u003e25-year-old female medical student\u003c\/strong\u003e undergoes a routine ultrasound of the neck during a radiology rotation and is found to have a \u003cstrong\u003e7-mm nodule on the right side\u003c\/strong\u003e and a \u003cstrong\u003e5-mm nodule on the left side\u003c\/strong\u003e. At the insistence of the radiologist, she undergoes a biopsy on both sides, and both show papillary carcinoma. What should be done?\u003c\/p\u003e\n\n\u003cp\u003eObviously, the optimal treatment with a diagnosis of carcinoma on both sides would be total thyroidectomy. However, in a 25-year-old woman with a long life ahead, credible academic responsibilities, and proposed family responsibilities, \u003cstrong\u003eactive surveillance is a very reasonable option\u003c\/strong\u003e based on the patient's preferences, values, and risk tolerance. Total thyroidectomy may represent excessive therapy in this patient, requiring lifetime supplementation of thyroid medication. Even in the best of hands, there is a \u003cstrong\u003e2% risk of complications\u003c\/strong\u003e related to nerve injury or temporary or permanent hypoparathyroidism (underactive parathyroid glands). Adjusting these patients to thyroid medication may be easy in principle but more difficult in practice—patients often complain that \"I just don't feel the same.\" Quality of life in these individuals needs to be better studied.\u003c\/p\u003e\n\n\u003ch2 id=\"ideal-candidates\"\u003eWho Should Be Referred for Active Surveillance?\u003c\/h2\u003e\n\n\u003cp\u003eIn conjunction with Professor Miyauchi, Tuttle and his group from MSK defined \u003cstrong\u003ethree interrelated domains\u003c\/strong\u003e for patient selection: tumor and ultrasound characteristics, medical team characteristics, and patient characteristics. Based on these decision-making domains, a clinical framework was developed to classify patients as \u003cstrong\u003eideal, appropriate, or inappropriate\u003c\/strong\u003e for active surveillance.\u003c\/p\u003e\n\n\u003ch3\u003eTumor Characteristics for Ideal Candidates\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eSolitary intrathyroidal nodule (a single nodule confined within the thyroid)\u003c\/li\u003e\n  \u003cli\u003eWell-defined borders\u003c\/li\u003e\n  \u003cli\u003eTumors surrounded by normal thyroid tissue\u003c\/li\u003e\n  \u003cli\u003eNo extrathyroidal extension (no spread beyond the thyroid)\u003c\/li\u003e\n  \u003cli\u003eNo evidence of metastatic disease to the central compartment or lateral compartment (neck lymph nodes)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePatient Characteristics for Ideal Candidates\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eAge above \u003cstrong\u003e60 years\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003ePatient acknowledges that future surgery may be required\u003c\/li\u003e\n  \u003cli\u003ePatient cooperation and compliance with regular follow-up\u003c\/li\u003e\n  \u003cli\u003eIf present, comorbidities (other health conditions) are prioritized in the management plan rather than the cancer itself\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMany patients may have another concurrent malignancy (a different cancer), which—unlike micropapillary carcinoma—is a major decision maker and should be the focus of initial disease management.\u003c\/p\u003e\n\n\u003ch3\u003eMedical Team Characteristics\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eExperienced multidisciplinary team\u003c\/li\u003e\n  \u003cli\u003eExperienced ultrasonographer (ultrasound technician)\u003c\/li\u003e\n  \u003cli\u003eAppropriate data collection and departmental support\u003c\/li\u003e\n  \u003cli\u003eAppropriate coordination and decision making between the surgeon and the endocrinologist after appropriate imaging studies such as ultrasound and, when necessary, a CT scan\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTumors with \u003cstrong\u003eirregular margins\u003c\/strong\u003e should be carefully evaluated, as there is a likely higher incidence of both extrathyroidal extension and nodal metastasis. Patients classified as \u003cstrong\u003einappropriate\u003c\/strong\u003e for active surveillance include those with:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eInvolvement of the surrounding soft tissues adjacent to the recurrent laryngeal nerve (the nerve that controls the vocal cords)\u003c\/li\u003e\n  \u003cli\u003eGross extracapsular spread (tumor extending outside the thyroid capsule)\u003c\/li\u003e\n  \u003cli\u003eTumors with metastatic disease either to the central or lateral compartment\u003c\/li\u003e\n  \u003cli\u003eNeedle biopsy suggestive of an aggressive variety of tumor\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEven though \u003cstrong\u003eBRAF\u003c\/strong\u003e (a genetic mutation) has been included in some fine-needle aspiration biopsies, the authors would not consider that a major decision-maker unless the tumor itself shows aggressive clinical features.\u003c\/p\u003e\n\n\u003cp\u003eAge has always been a concern, but there is good data from Miyauchi's group showing that even young patients can be enrolled into active surveillance, with the understanding that approximately \u003cstrong\u003e40–50% may require surgery\u003c\/strong\u003e eventually. However, surgery may be deferred until an opportune time in their life or until there is a distinct increase in tumor size. Interestingly, older patients do very well with active surveillance, with very little tumor growth over time.\u003c\/p\u003e\n\n\u003ch2 id=\"strategy\"\u003eThe Observational Approach: What Monitoring Looks Like\u003c\/h2\u003e\n\n\u003cp\u003eSeveral factors go into the decision-making process for observation. Generally, patients will require \u003cstrong\u003eserial ultrasounds\u003c\/strong\u003e (repeated ultrasound examinations over time). Initially, the authors prefer to obtain ultrasounds of the thyroid and cervical lymph node chains \u003cstrong\u003eevery 6 months\u003c\/strong\u003e to give confidence to the patient about the stability of the thyroid nodule.\u003c\/p\u003e\n\n\u003cp\u003eThyroid hormone therapy is recommended if needed to keep the thyroid stimulating hormone (TSH) in the normal range and less than about \u003cstrong\u003e3 mIU\/L\u003c\/strong\u003e. Once thyroid function is known to be satisfactory, ultrasounds are usually repeated \u003cstrong\u003eevery year\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eFor the patient who is a minimalist (prefers less intervention), the follow-up strategy includes ultrasound every 6 months for the first 1 or 2 years, and then every year after that. If there is a substantial change in tumor volume or nodal metastasis, surgery should be considered—which happens in \u003cstrong\u003eless than 10% of patients\u003c\/strong\u003e according to many studies.\u003c\/p\u003e\n\n\u003ch2 id=\"surgical-indications\"\u003eWhen Surgery Becomes Necessary\u003c\/h2\u003e\n\n\u003cp\u003eThe indications for surgical intervention under observation include:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncrease in the size of the tumor more than 3 mm.\u003c\/strong\u003e Although 3 mm is used as a general consideration, generally any increase in tumor size of more than \u003cstrong\u003e100%\u003c\/strong\u003e should prompt consideration for surgical intervention or more careful follow-up.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIdentification of metastatic nodes in the central compartment\u003c\/strong\u003e, which happens in approximately 2–3% of people.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDirect invasion of the surrounding tissues\u003c\/strong\u003e should be a strong indication for surgery. This is best evaluated with a good ultrasound and cross-sectional imaging if needed. Posterior tumors (located at the back of the thyroid) are not the best for observation, and anterior tumors in the isthmic area (the bridge connecting the two thyroid lobes) may invade surrounding structures.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient preference\u003c\/strong\u003e is important and can change over time. Sometimes young individuals switch to the surgical approach for a variety of reasons, including anxiety after discussion with friends or family members, the gravity of the word \"cancer,\" or occasionally hearing about other people's concerns about thyroid cancer progression.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUncommonly, surgical intervention may be considered for insurance issues or other indications for thyroid surgery\u003c\/strong\u003e, such as concurrent hyperparathyroidism (overactive parathyroid glands) or an increase in benign thyroid nodules. Kidney or liver donations are usually not accepted with a diagnosis of active cancer, and surgery may be considered to facilitate donation. Likewise, transplant centers usually consider a known cancer to be a contraindication to receiving an organ transplant, and thus surgery may be required to render the patient disease-free to facilitate organ transplantation.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIt should be recognized that active surveillance requires complete understanding in a triangular fashion involving the surgeon, the endocrinologist, and the patient (as well as family members). The strategy of active surveillance will result in approximately \u003cstrong\u003e10% migrating from active surveillance to surgery\u003c\/strong\u003e—5% due to an increase in the size of the thyroid nodule or new lymph nodes, and 5% mainly because of patient and family wishes. However, in all reported series, there were \u003cstrong\u003eno adverse findings\u003c\/strong\u003e either at the time of surgery or in outcomes. Long-term follow-up has been quite satisfactory, with no adverse or deleterious effect on long-term outcome or mortality.\u003c\/p\u003e\n\n\u003ch2 id=\"decision-making\"\u003eMedical Decision Making: Maximalist vs. Minimalist Approaches\u003c\/h2\u003e\n\n\u003cp\u003eOnce again, decision-making rests on the patient, the surgeon, and the endocrinologist who will monitor and follow the patient. It is very important to ensure the patient understands the reason behind active surveillance. The idea is \u003cstrong\u003enot to defer treatment or offer inferior treatment\u003c\/strong\u003e but to continuously monitor a tumor that the patient may live with for a long time.\u003c\/p\u003e\n\n\u003cp\u003eWhether a patient will need surgery in the near or distant future is difficult to determine; however, most patients can be monitored very well based on international studies. Several international studies and meta-analyses have shown that the overall risk of an increase in the size of the thyroid nodule is about \u003cstrong\u003e3–5%\u003c\/strong\u003e, and new nodal metastasis is noted in \u003cstrong\u003eless than 2%\u003c\/strong\u003e of people.\u003c\/p\u003e\n\n\u003cp\u003eThe patients who generally switch to surgery are those with considerable anxiety or family members pushing them toward surgery. In this aspect, it is very important to understand the difference between \u003cstrong\u003emaximalist\u003c\/strong\u003e and \u003cstrong\u003eminimalist\u003c\/strong\u003e approaches. Pamela Hartzband and Jerome Groopman have published on the subject of medical decision making, including how to decide what is right for you in terms of these approaches.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMaximalists\u003c\/strong\u003e prefer aggressive surgery (they \"want surgery yesterday\"). These patients are not ideal candidates for observation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMinimalists\u003c\/strong\u003e believe that tumors of this type can be observed to monitor whether surgery would be appropriate at an opportune time. These are the right candidates for observation.\u003c\/li\u003e\n  \u003cli\u003ePatients who remain \u003cstrong\u003edoubtful\u003c\/strong\u003e are not the best candidates.\u003c\/li\u003e\n  \u003cli\u003ePatients who are \u003cstrong\u003etechnologically oriented\u003c\/strong\u003e (preferring the latest technological interventions) are also not the best candidates.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThere must be a good discussion between the patient and the treating physician. It is also important that the surgeon works with an endocrinologist who shares the same philosophy. The decision about surgery versus observation will depend upon a dedicated, high-quality ultrasound to ensure there are no adverse imaging features that would push the patient toward surgery.\u003c\/p\u003e\n\n\u003cp\u003eThere are always cost concerns; however, the whole idea is to try to avoid surgery in these incidentalomas (tumors found incidentally). In principle, a significant number of the general population—approximately \u003cstrong\u003e10%\u003c\/strong\u003e—may be harboring microscopic papillary carcinoma, and we do not need to push every one of them toward surgery when the diagnosis is made incidentally. Needless to say, if the tumor is palpable (can be felt) or the patient is symptomatic, they will definitely need surgery.\u003c\/p\u003e\n\n\u003cp\u003eThe philosophy of the maximalist is generally \"Why wait? More is better.\" While minimalists take a \"Less is more\" approach and feel that any unintended consequences of surgery outweigh potential benefits. This is where the philosophy of believers and doubters, and the idea of technology orientation versus naturalistic orientation, comes in. Patients and their families must understand the philosophy behind observation. The surgeon and the endocrinologist need to explain that this is what they would also recommend for their own family members and that there is no rush to operate, especially in young people who may have concerns about surgical complications.\u003c\/p\u003e\n\n\u003cp\u003eAlthough thyroidectomy surgery is generally quite safe, complications do occur in the range of \u003cstrong\u003e1–3%\u003c\/strong\u003e, including nerve injury and parathyroid problems. However, it is important to note that complication rates may be \u003cstrong\u003esignificantly higher when thyroid surgery is done outside of major medical centers\u003c\/strong\u003e. Some patients may need thyroid medication, and getting adjusted to thyroid medication and maintaining quality of life are important concerns. The old philosophy \"let the punishment fit the crime\" is critical in the management of these patients.\u003c\/p\u003e\n\n\u003cp\u003eIt is also important to make the patient and their family aware that the thyroid cancer diagnosis was totally incidental, the tumor is a microcarcinoma, and it is quite likely it may have been there for many years. Patients need reassurance that this particular cancer is not detrimental to their health and will not lead to a major catastrophe in the future. The benefit of monitoring to see if there is any change and deferring surgery until then should be emphasized.\u003c\/p\u003e\n\n\u003ch2 id=\"adverse-features\"\u003eAdverse Features of Papillary Microcarcinoma\u003c\/h2\u003e\n\n\u003cp\u003eCertain thyroid tumor features are considered adverse and would argue against active surveillance:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClinical and radiological features:\u003c\/strong\u003e irregular margins, infiltrating borders\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadiological or clinical gross extrathyroidal extension\u003c\/strong\u003e (tumor extending outside the thyroid)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePresence of nodal metastasis\u003c\/strong\u003e (spread to lymph nodes)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDistant metastasis\u003c\/strong\u003e (spread to other parts of the body)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCytology report showing aggressive pathology\u003c\/strong\u003e (concerning features under the microscope)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMulticentric tumor (tumors in multiple locations within the thyroid) is always a debatable question; however, generally the combination of all multicentricity below 1 cm does not have any major adverse features. \u003cstrong\u003eLocation of the tumor is also important\u003c\/strong\u003e—for example, the disease management team needs to assess whether the tumor is against the posterior wall of the trachea (windpipe) or in other high-risk locations.\u003c\/p\u003e\n\n\u003cp\u003eThe decision-making about active surveillance rests on several factors: tumor volume, tumor location, rate of change of the tumor (doubling time), and the follow-up strategy that can be maintained.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis review has significant implications for patients diagnosed with micropapillary thyroid carcinoma. The key takeaway is that \u003cstrong\u003eimmediate surgery is not always necessary\u003c\/strong\u003e for these tiny cancers. The evidence from multiple international studies involving thousands of patients consistently shows that:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eMore than \u003cstrong\u003e90% of tumors remain stable\u003c\/strong\u003e during observation\u003c\/li\u003e\n  \u003cli\u003eFewer than \u003cstrong\u003e10% of patients\u003c\/strong\u003e will eventually need surgery due to tumor growth\u003c\/li\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e2–3% develop lymph node metastasis\u003c\/strong\u003e, which does not impact long-term outcomes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo patients have died\u003c\/strong\u003e from thyroid cancer under active surveillance\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor patients, this means the diagnosis of micropapillary thyroid carcinoma should not automatically trigger anxiety about needing immediate surgery. Instead, patients should have an informed discussion with their medical team about whether active surveillance is appropriate for their specific situation. The decision should consider tumor characteristics (size, location, margins), patient characteristics (age, comorbidities, preferences), and the expertise of the medical team.\u003c\/p\u003e\n\n\u003cp\u003eThe authors emphasize that the decision is more important than the incision—meaning the thoughtful choice of management strategy matters more than the surgical procedure itself. The biology of micropapillary carcinoma is much different from other aggressive human cancers, and treatment should reflect this understanding.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations and Uncertainties\u003c\/h2\u003e\n\n\u003cp\u003eWhile the evidence strongly supports active surveillance, the authors acknowledge several limitations and uncertainties:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWho should be offered active surveillance\u003c\/strong\u003e remains uncertain, and there is no universal consensus on ideal candidates.\u003c\/li\u003e\n  \u003cli\u003eApproximately \u003cstrong\u003e10% of patients switch to surgery\u003c\/strong\u003e primarily due to the \"fear factor\" rather than actual tumor growth or lymph node metastasis—highlighting the psychological challenges of living with a cancer diagnosis.\u003c\/li\u003e\n  \u003cli\u003eLong-term data beyond 10–15 years of observation are still being accumulated, though current evidence is reassuring.\u003c\/li\u003e\n  \u003cli\u003eThe optimal follow-up interval and duration have not been definitively established, though the authors recommend ultrasound every 6 months initially, then annually.\u003c\/li\u003e\n  \u003cli\u003eQuality of life after thyroidectomy needs to be better studied, as some patients report not feeling the same even with appropriate thyroid hormone replacement.\u003c\/li\u003e\n  \u003cli\u003eYounger patients (under 40) have a higher likelihood of eventually requiring surgery (approximately 40–50%), though surgery can often be deferred to an opportune time.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this clinical review, here are actionable recommendations for patients diagnosed with micropapillary thyroid carcinoma:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHave an informed discussion with your medical team.\u003c\/strong\u003e Ask whether active surveillance is appropriate for your specific tumor characteristics and personal situation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your tumor's features.\u003c\/strong\u003e Ask about tumor size, margins, location, and whether there is any evidence of extrathyroidal extension or lymph node involvement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider your own preferences and risk tolerance.\u003c\/strong\u003e Are you a minimalist who prefers less intervention, or a maximalist who wants aggressive treatment? Be honest with yourself and your doctor.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEnsure you have access to a high-quality ultrasound and experienced medical team.\u003c\/strong\u003e The success of active surveillance depends on reliable monitoring.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCommit to regular follow-up.\u003c\/strong\u003e This typically means ultrasound every 6 months for the first 1–2 years, then annually thereafter.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow the warning signs that warrant surgery:\u003c\/strong\u003e tumor growth of more than 3 mm or more than 100% increase in size, new lymph node metastasis, or direct invasion of surrounding tissues.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemember that you can change your mind.\u003c\/strong\u003e Active surveillance is not a lifetime commitment—you can opt for surgery at any time if your anxiety becomes unmanageable or circumstances change.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek reassurance.\u003c\/strong\u003e The evidence shows that no patients under active surveillance have died from thyroid cancer, and the vast majority never need surgery.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eBased on existing literature and clinical experience, the authors conclude that \u003cstrong\u003eactive surveillance is an appropriate strategy for monitoring micropapillary carcinoma\u003c\/strong\u003e. The key is proper patient selection, a committed multidisciplinary team, and a clear understanding between patients and their physicians about the goals and methods of this approach.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is active surveillance for micropapillary thyroid carcinoma?\u003c\/h3\u003e\n\u003cp\u003eActive surveillance is a strategy of careful monitoring instead of immediate surgery for small thyroid cancers less than 1 centimeter. It involves regular ultrasounds to watch for any changes. This approach is a deliberate, evidence-based choice for appropriately selected patients, not inferior treatment.\u003c\/p\u003e\n\u003ch3\u003eWho is an ideal candidate for active surveillance?\u003c\/h3\u003e\n\u003cp\u003eIdeal candidates are typically over 60 years old, have a single intrathyroidal nodule with well-defined borders, no extrathyroidal extension, and no lymph node metastasis. They must be willing to comply with regular follow-up and understand that surgery may be needed later. Other health conditions may take priority.\u003c\/p\u003e\n\u003ch3\u003eWhat happens during active surveillance?\u003c\/h3\u003e\n\u003cp\u003eYou will have serial ultrasounds of the thyroid and neck lymph nodes. Initially, ultrasounds are done every 6 months for the first 1-2 years, then annually. Thyroid hormone therapy may be given to keep TSH in the normal range. If there is significant tumor growth or new lymph nodes, surgery is considered.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks of active surveillance?\u003c\/h3\u003e\n\u003cp\u003eThe main risk is that the tumor may grow or spread to lymph nodes, but this happens in a minority of patients. In studies, fewer than 10% of tumors grow, and only 2-3% develop lymph node metastasis. No patients under active surveillance have died from thyroid cancer in published studies.\u003c\/p\u003e\n\u003ch3\u003eWhen is surgery recommended during active surveillance?\u003c\/h3\u003e\n\u003cp\u003eSurgery is recommended if the tumor increases in size by more than 3 mm or more than 100%, if new lymph node metastasis appears, or if there is direct invasion of surrounding tissues. Patient preference or anxiety can also lead to surgery. About 10% of patients eventually switch to surgery.\u003c\/p\u003e\n\u003ch3\u003eCan young patients choose active surveillance?\u003c\/h3\u003e\n\u003cp\u003eYes, but they have a higher likelihood of eventually needing surgery, approximately 40-50%. However, surgery can often be deferred to an opportune time in their life. The decision should be based on patient preferences, values, and risk tolerance, with a full discussion with the medical team.\u003c\/p\u003e\n\u003ch3\u003eWhat are the benefits of active surveillance compared to surgery?\u003c\/h3\u003e\n\u003cp\u003eActive surveillance avoids the risks of surgery, such as neck scarring, nerve injury, parathyroid problems, and the need for lifelong thyroid medication. It also avoids potential quality-of-life issues after thyroidectomy. Most patients under surveillance never need surgery, and no deaths from thyroid cancer have been reported.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Active surveillance for micropapillary thyroid carcinoma- a clinical review Tuttle\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e \u003ca href=\"https:\/\/doi.org\/10.21037\/gs-22-558\" target=\"_blank\" rel=\"noopener\"\u003e10.21037\/gs-22-558\u003c\/a\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Ashok R. Shaha, MD, FACS (Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY) and R. Michael Tuttle, MD (Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Gland Surgery, Vol 13, No 1, January 2024, pages 100-107\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.21037\/gs-22-558\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSubmitted:\u003c\/strong\u003e September 26, 2022 | \u003cstrong\u003eAccepted:\u003c\/strong\u003e May 8, 2023 | \u003cstrong\u003ePublished online:\u003c\/strong\u003e May 29, 2023\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace professional medical advice. Always consult with your healthcare provider about your specific medical situation.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47377201004700,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.de\/products\/active-surveillance-for-micropapillary-thyroid-carcinoma-a-patients-guide-to-understanding-your-options","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}